Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Artículo en Inglés | IMSEAR | ID: sea-45393

RESUMEN

The effect of nebulized salbutamol on oxygen saturation in COPD was evaluated in this study. Twenty patients aged 56-75 years with stable COPD were recruited to the study. All patients received 5 mg of salbutamol nebulizer driven by oxygen at 8 L/min. The SaO2 was then measured continuously and readings were taken before and every minute after salbutamol inhalation by face mask. Following treatment, mean SaO2 was significantly lower than preinhalation values. The desaturation occurred from 3 minutes and reached the maximum desaturation at 15 minutes postinhalation. At 30 minutes, SaO2 had returned to baseline values. The findings suggest that salbutamol nebulization induced prolonged desaturation in COPD.


Asunto(s)
Administración por Inhalación , Anciano , Albuterol/administración & dosificación , Broncodilatadores/administración & dosificación , Femenino , Humanos , Enfermedades Pulmonares Obstructivas/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Consumo de Oxígeno/efectos de los fármacos , Simpatomiméticos/administración & dosificación
2.
Artículo en Inglés | IMSEAR | ID: sea-43851

RESUMEN

Our study suggests that the administration of bronchodilator drug via nebulizer powered by flow rate 6 L/min is more suitable in COPD patients. The oxygen flow rates should not be given more than 6 L/min. In this study, we recruited COPD patients in a stable stage, in whom the risk of hyperoxic induced hypercarbia is less than in the acute exacerbation stage. Thus, in acute exacerbation stage of the COPD patients, the rise of carbondioxide should be higher. We recommend that the COPD patients should receive bronchodilator drug via the nebulizer, especially in acute exacerbation stage, with oxygen flow rate not more than 6 L/min. The medical personnel must closely observe the clinical signs of the patients to prevent the hazard of carbondioxide retention.


Asunto(s)
Anciano , Albuterol/administración & dosificación , Velocidad del Flujo Sanguíneo/efectos de los fármacos , Estudios Cruzados , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Enfermedades Pulmonares Obstructivas/diagnóstico , Masculino , Persona de Mediana Edad , Monitoreo Fisiológico , Nebulizadores y Vaporizadores , Consumo de Oxígeno , Ápice del Flujo Espiratorio/efectos de los fármacos , Volumen de Ventilación Pulmonar/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA